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People who inject drugs (PWID) are at an elevated risk of infection by human immuno-
deficiency virus (HIV) or hepatitis C virus (HCV). In many high-income countries, needle
and syringe exchange programs (NSPs) have been associated with reductions in blood-
borne infections. However, there is not a good understanding of the effectiveness of NSP
in low- and middle-income countries and transitional-economy countries. A systematic
literature review, based on the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines, was utilized to collect primary study data on the coverage of
NSP programs and the changes in HIV and HCV infection over time among PWID in low-
and middle-income and transitional countries (LMICs). We included studies that reported
laboratory measures of HIV or HCV and at least 50% coverage of the local injecting popu-
lation (either through direct use or through secondary exchange). We also included na-
tional reports of newly reported HIV cases in countries that had national level data for
PWID in conjunction with NSP scale-up and NSP implementation. Included in the review
were studies of 11 NSPs with high-coverage from Bangladesh, Brazil, China, Estonia, Iran,
Lithuania, Taiwan, Thailand, and Vietnam. In five studies, the HIV prevalence decreased
(ranged from 3% to 15%) and in three studies the HCV prevalence decreased (ranged
from 4.2% to 10.2%). In two studies, the HIV prevalence increased (ranged from 5.6% to
14.8%). The HCV incidence remained stable in one study. Of the four national reports of
newly reported HIV cases, three studies reported decreases during the expansion of the
NSP, and ranged from 30% to 93.3%; however, one national report documented an in-
crease in HIV cases (37.6%). The estimated incidence among new injectors decreased in
three studies with the reductions ranging from 11/100 person-years at risk to 16/100
person-years at risk. The data, although not fully consistent, generally support the effec-
tiveness of NSP in reducing HIV and HCV infection in LMICs. If high coverage is achieved,
NSP appears to be as effective in LMICs as in high-income countries. To identify and correct
contributing problems, additional monitoring and evaluation research is needed for NSPs
in which reductions in HIV/HCV infection among PWID are not occurring.
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People who inject drugs (PWID) are at an elevated risk for
blood-borne infections [e.g., human immunodeficiency virus
(HIV) and hepatitis C (HCV)], and the prevalence of these
blood-borne infections among PWID has surpassed 20% in
many developed and developing countries [1]. The purpose of
this presentation was: (1) to document structural level needle
and syringe programs (NSPs) [2] or opiate substitution therapy
(OST) programs that are operational in low- and middle-
income countries (LMICs) and (2) to present findings related
to changes in blood-borne infection among participants in
NSPs and changes in the retention of participants over time in
OST programs.
We chose to focus on the countries that are defined as “low
income” by World Bank classification. High-income countries
were not included because there is an abundance of docu-
mentation of the success of NSPs and OST programs in these
locations. For this reason, we wanted to compare the success
of these high-income programs to programs implemented in
LMICs because many programs in LMICs have only recently
been implemented and may not have adequate resources.
Mutli-person use of needles and syringes is a very efficient
way of transmitting blood-borne infections among people
who inject drugs. To reduce the transmission of HIV, HCV, and
other blood-borne infections, it is imperative that clean in-
jection equipment be made available to drug users who
continue to inject. Some LMICs are documenting HIV preva-
lence among PWIDs that has surpassed 20%; therefore, it is
important to offer services to drug users before the HIV
prevalence reaches much higher levels.
Through modeling studies conducted on PWID pop-
ulations, wewere able to determine that the structural level of
NSP services is obtained when at least 10 needles/syringes are
available per PWID per year in a respective location. Once a
NSP reaches this level of coverage, more noticeable changes
over time can occur in the incidence and prevalence of blood-
borne infections, especially among new PWID. This has been
documented in several studies of NSPs in high-income coun-
tries such as Australia, Canada, the United States, and the
United Kingdom.
Opiate substitution treatment is a key component in pre-
venting overdose, reducing illicit opiate use, and preventing
the risk of blood-borne virus infection. Multiple studies have
highlighted the success of OST in high-income countries and
have documented reductions in relapse, overdose, and asso-
ciated risky drug use behaviors.2. Methods
To obtain the necessary studies required for this review, we
performed a systematic literature search [by utilizing the
Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines] to collect coverage informa-
tion on NSPs and OST programs and to collect surveillance
data or longitudinal cohort data with baseline and follow-up
HIV testing and/or HCV testing or changes in the retention
of OST participants over time. Needle and syringe exchangeprogram studies have to document changes in blood-borne
infection through the serologic testing of participants. Self-
reported information was not included because of the unre-
liability of disease reporting among participants. Changes in
blood-borne infection also had to be documented during NSP
implementation or during the scale-up of NSP services.We did
not include studies that documented changes after the full
implementation of a NSP or prior to the full-scale imple-
mentation of a NSP. There had to be documentation of the
implementation of an OST program or ongoing OST program
in a sample of drug users. Longitudinalmeasurements needed
to document changes in the retention of OST participants. We
excluded any OST program study that did not utilize bupe-
norphine ormethadone for the OST pharmacologic treatment,
and we excluded OST program studies that only included
participants or individuals from prison or institutionalized
settings.
For all included studies, coding forms were developed and
each study was double checked for accuracy prior to data
analysis. Risk of bias was assessed for each study by utilizing
the methodology developed from the Cochrane Collaboration
of Systematic Reviews.3. Results
Seventeen countries were represented in the systematic re-
views of NSPs and OST programs in LMICs. There were 12
studies that examined NSPs in relation to changes in blood-
borne infection, and 63 programs documented the change in
OST retention over time. The countries represented in the
analysis were Afghanistan, Bangladesh, Brazil, China, Georgia
(Republic), India, Indonesia, Iran, Kyrgyzstan, Lithuania,
Malaysia, Mauritius, Taiwan, Tanzania, Thailand, Ukraine,
and Vietnam.
Among the NSP studies, seven of the nine locations that
analyzed HIV prevalence showed decreases during and after
the full implementation of structural level NSPs. Three loca-
tions that analyzed HCV prevalence showed decreases, but
one study reported the stabilization of newly reported HCV
cases among the NSP participants. Among the national sur-
veillance reports, three of four countries documented de-
creases in newly reported HIV cases during NSP
implementation and expansion, whereas one country re-
ported a slight increase in newly reported cases that was
directly correlated with the lower number of syringes
distributed during the later years of the NSP.
Opiate substitution therapy programs in LMICs achieved
good levels of retention of their participants, which was
similar to the findings of studies in high-income countries.
The overall retention value of OST programs in LMICs was
54.3% after 12months, which is above the 50%minimum level
documented as a baseline for retention success in OST pro-
grams. There was a slightly higher retention level (56.6%) of
participants who were on amethadone regimen, compared to
the retention level (48.3%) of participants who were on a
bupenorphine regimen; however, this difference was not
statistically significant. We additionally found that the
retention of participants was unrelated to the dosage of the
pharmacologic substance, although most studies adhered to
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Needle and syringe exchange programs and OST programs
are an integral part of HIV harm reduction. They are associ-
ated with a reduction in overdoses, blood-borne infection
transmission, crime and associated risky behaviors, and they
are associated with an increased quality of life. Programs
implemented on a large scale appear to be as successful in
LMICs as they are in high-income countries. As these pro-
grams gainwider acceptance, new pilot programswill begin to
emerge, which is the situation with new OST programs and
NSPs present in Eastern Europe and southeast Asia where
injection-related infection transmission continues to occur at
high levels. It will be important to continue to monitor exist-ing and new programs as they emerge in LMICs to ensure that
the outcomes obtained among participants are comparable to
already established programs in high-income locations.
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